Země: Irsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
GEMCITABINE
Generics (UK) Limited
GEMCITABINE
2 Grams
Pdr for Soln for Infusion
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
Gemcitabine Mylan 38 mg/ml, powder for solution for infusion PACKAGE LEAFLET: INFORMATION FOR THE USER GEMCITABINE MYLAN 200MG & GEMCITABINE MYLAN 1G, POWDER FOR SOLUTION FOR INFUSION GEMCITABINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What GEMCITABINE MYLAN is and what it is used for 2. What you need to know before you use GEMCITABINE MYLAN 3. How to use GEMCITABINE MYLAN 4. Possible side effects 5. How to store GEMCITABINE MYLAN 6. Contents of the pack and other information 1. WHAT GEMCITABINE MYLAN IS AND WHAT IT IS USED FOR Gemcitabine Mylan belongs to a group of medicines called “cytotoxics”. These medicines kill dividing cells, including cancer cells. Gemcitabine Mylan may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer. Gemcitabine Mylan is used in the treatment of the following types of cancer: non-small cell lung cancer (NSCLC), alone or together with cisplatin pancreatic cancer. breast cancer, together with paclitaxel. ovarian cancer, together with carboplatin. bladder cancer, together with cisplatin. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE GEMCITABINE MYLAN DO NOT USE GEMCITABINE MYLAN: - if you are allergic to gemcitabine or any of the other ingredie Přečtěte si celý dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gemcitabine Mylan 2g, powder for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 100 ml vial contains 2000 mg of gemcitabine for reconstitution in 50 ml of solvent. 1ml of reconstituted solution contains 38mg of gemcitabine Excipients Each 2000 mg vial contains 35mg (1.5 mmol) sodium. For the full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for infusion. White to off-white plug or powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Gemcitabine should only be prescribed by a physician qualified in the use of anti-cancer chemotherapy. Recommended p Přečtěte si celý dokument